Board Of Directors
Our Directors are well-respected individuals with a diverse range of views, experience and knowledge. They are responsible for governing the VRF, establishing policy, setting priorities, and making final grant decisions. All Directors are unpaid volunteers serving staggered five-year terms, for a maximum of ten years.
Mr. Dmitry Aksenov, MSc, MBA
Dmitry Aksenov founded the Vitiligo Research Foundation in 2010, as a means of organizing and coordinating vitiligo research across the world. A self-made man, successful entrepreneur and philanthropist, Dmitry is often said to have revolutionized the Russian real estate development market. He graduated with the highest distinction and earned his MSc in physics in 1989. In the early 2000s, Dmitry introduced the first energy-efficient and affordable houses to the Russian market, and created thousands of jobs in the Moscow region. He actively promotes a cultural dialogue between East and West through the Vienna Art Fair, which he acquired in 2012 and has since turned it into an annual, must-see contemporary art event.
As the father of a child with vitiligo, he began his involvement in combating the disease by consulting with leading dermatologists and identifying recent breakthroughs in medical research that could cure his daughter. When he discovered that very little funding went towards new work in vitiligo, he spent two years identifying and recruiting the most visionary scientists in the field to work together.
Unwilling to accept the limited treatment options available to vitiligo patients, Dmitry established the Vitiligo Research Foundation. He teamed up with leading experts from academia and the biopharma industry to accelerate the basic science and create connections between academic scientists and those who commercially develop drugs. Since its inception, the VRF has become one of the leading supporters of vitiligo research and treatment in the world. Dmitry is now dedicated to the mission of the VR Foundation in preventing other families having to endure a similar battle with this distressing skin disease.
Prof. Torello Lotti, MD
Chair of the Board
Prof. Jana Hercogova, MD
Prof. Jana Hercogova is the past-President of the European Academy of Dermatology and Venereology. Her positions include Chairwoman at the Department of Dermatology, Charles University Prague since 1995 and also Scientific Board Member of the 2nd Medical Faculty, since 1999, Secretary General of the Czech Academy of Dermatology and Venereology since 2012, Board Member of the European Society for Cosmetic and Aesthetic Dermatology since 2000, Professor of Dermatology, Venereology, Cell Biology and Psychocutaneous Medicine at the International Faculty of the "Centro Interuniversitario di Dermatologia Biologica e Psicosomatica", Italy since 2001, Visiting Professor University of Siena, Italy since 2003, Honorary Professor at the No 1 Hospital in Shenyang, China since 2011.
Prof. Mark Lebwohl, MD
President-elect of the American Academy of Dermatology, Prof. Lebwohl leads one of the most renowned dermatology programs in the nation. Under his direction, extraordinary recruits in medical dermatology have developed safer, more effective therapies in skin cancer, psoriasis, vitiligo, eczema, and many other dermatologic diseases. He is professor and chairman of the department of dermatology at The Mount Sinai School of Medicine. Lebwohl is president of the New York State Society of Dermatology and has served as president of the Manhattan Dermatologic Society and chairman of the Dermatology Section of the New York Academy of Medicine. He is also a member of the Medical Board of the National Psoriasis Foundation. Mark Lebwohl has chaired numerous symposia and has written or edited several books, including the leading book on dermatologic therapy, - Treatment of Skin Disease. He has authored or co-authored over 500 publications including articles, chapters and abstracts. Prof. Lebwohl is actively involved in clinical trials of many new dermatologic treatments.
Prof. Robert Schwartz, MD
One of the America's foremost dermatologists, Robert Schwartz is Professor and Head of Dermatology at New Jersey Medical School. He is also Professor of Medicine, Professor of Pediatrics, Professor of Pathology and Laboratory Medicine and Professor of Preventive Medicine and Community Health at the New Jersey Medical School. Professor Schwartz has been elected a Member Honoris Causa of fifteen National Dermatologic Societies in Europe. He has lectured widely, including eighteen consecutive years on the faculty of the annual meeting of the American Academy of Dermatology, as a featured speaker dozens of dermatological congresses. He is a past President of the Dermatology Section of the New York Academy of Medicine, and in 2009 began a five-year term on the Board of Directors of the International Society of Dermatology. He served as Chair of the VRF Scientific Advisory Board from May 2010 through December 2014.
I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.
What is coming?
Vitiligo Working Group meeting
4th annual meeting of the Vitiligo Working Group will be held on Thursday, March 3rd, 2016. For details and registration, please contact Angie Parks-Miller, VWG Coordi...03 March 2016 10:00, Washington, DC
XVI Master Class on Vitiligo and Pigmentary Disorders in Jakarta, Indonesia
Our XVI Master Class on Vitiligo and Pigmentary Disorders will be held in conjunction with the 12th International Congress of International Society of Cosmetic Dermato...02 April 2016 09:00, Jakarta, Indonesia
Who is prone to vitiligo?
Vitiligo affects 0.5-2% of the population, and occurs in all races and all social levels. Vitiligo can affect people of all ages, but often starts between the ages of ...
What's better: laser or phototherapy?
In a recent controlled study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA an...
Is it possible to stop the progression of vitiligo?
It is true that vitiligo progression could be stopped in 4 out of 5 cases by the use of potent systemic corticosteroids. However, systemic corticosteroids might ha...
I have a new job - should I tell colleagues about my vitiligo?
If you are starting a new job and you are concerned about stares and questions about your skin, try a proactive approach. When the time is right and you are feeling co...